Loading…
Reported covered position: StaffDir/Counsel,HouseOversight&GovtReformSubcommitteeMinority Counsel,HouseOversight&GovtReformCommitteeCounsel, House Committee on Standards of Official ConductLegislative Assistant & Counsel, Rep. Steny HoyerLegislative Assistant, Rep. Julian Dixon
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Elijah E. Cummings Lower Drug Costs Now Act
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2019 · fourth_quarter · 4T
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2019 · fourth_quarter · Q4
Source: Senate LDA
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Elijah E. Cummings Lower Drug Costs Now Act
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Prescription Drug Pricing Reduction Act of 2019
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123). Support for funding of Department of Homeland Security drug interdiction efforts.
An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018.
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to taxation of offshore revenue and corporate tax reform; H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Issues related to Medicare Part D reform proposals in budget and health care reform proposals. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to Medicare Part D reform proposals in budget and health care reform proposals. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. H.R.2430/S.934, FDA Reauthorization Act of 2017.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. H.R.2430/S.934, FDA Reauthorization Act of 2017.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Cybersecurity and American Cyber Competitiveness Act of 2013
Client: LILLY USA LLC · Firm: FORGE FEDERAL AFFAIRS LLC
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issues related to Medicare Part D in the Fiscal Cliff legislation, American Taxpayers Relief Act (H.R.8).
Issues related to the taxation of offshore entities. Issues related to H.R.8, American Taxpayer Relief Act of 2012 (Fiscal Cliff legislation).
Issues related to the taxation of offshore entities. Issues related to H.R.8, American Taxpayer Relief Act of 2012 (Fiscal Cliff legislation).
Issues related to Medicare Part D in the Fiscal Cliff legislation, American Taxpayers Relief Act (H.R.8).
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2019 · third_quarter · Q3
Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to pricing of prescription drugs. Monitoring H.R.3, Lower Drug Costs Now Act of 2019 and S.2543, Prescription Drug Pricing Reduction Act of 2019.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2019 · second_quarter · Q2
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2019 · first_quarter · Q1
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2018 · fourth_quarter · Q4
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2018 · third_quarter · Q3
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2018 · second_quarter · Q2
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2018 · first_quarter · Q1
Issues related to pricing of prescription drugs. Opposition to prescription drug importation and cuts to Medicare Part D funding; H.R.1892, Bipartisan Budget Act of 2018 (P.L.115-123). Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2017 · fourth_quarter · Q4
Monitored issues related to taxation of offshore revenue and corporate tax reform; H.R.1, Tax Cuts and Jobs Act (P.L.115-97).
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts.
Filing targets: HOUSE OF REPRESENTATIVES
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2017 · fourth_quarter · 4T
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2017 · third_quarter · Q3
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2017 · third_quarter · Q3
Issues related to Medicare Part D reform proposals in budget and health care reform proposals. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. P.L.115-52, FDA Reauthorization Act of 2017.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2017 · second_quarter · Q2
Issues related to minority cardiovascular health.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2017 · second_quarter · Q2
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issues related to Medicare Part D reform proposals in budget and health care reform proposals. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act. H.R.2430/S.934, FDA Reauthorization Act of 2017.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2017 · first_quarter · Q1
Issues related to minority cardiovascular health.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2017 · first_quarter · Q1
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts. Issues related to reauthorization of the Prescription Drug User Fee Act.
Issues related to Medicare Part D reform proposals in budget and health care reform proposals.
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2016 · fourth_quarter · Q4
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2016 · fourth_quarter · Q4
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to Medicare Part D reform proposals in budget and funding measures. Issues related to CMS initiative on Medicare Part B Drug Payment Model.
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2016 · third_quarter · Q3
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2016 · third_quarter · Q3
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2016 · second_quarter · Q2
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2016 · second_quarter · Q2
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Issues related to Medicare Part D reform proposals in budget and funding measures. Issues related to CMS initiative on Medicare Part B Drug Payment Model.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary. Issues related to IP protections for pharmaceuticals and biologics in Trans Pacific Partnership trade agreement.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2016 · first_quarter · Q1
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts.
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary. Issues related to IP protections for pharmaceuticals and biologics in Trans Pacific Partnership trade agreement.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2016 · first_quarter · Q1
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2015 · fourth_quarter · Q4
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2015 · fourth_quarter · Q4
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Issues related to Medicare Part D reform proposals in budget and funding measures.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2015 · third_quarter · Q3
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2015 · third_quarter · Q3
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Monitored issues related to taxation of offshore entities and corporate tax reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2015 · second_quarter · Q2
Issues related to minority cardiovascular health.
Filing targets: HOUSE OF REPRESENTATIVES
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2015 · second_quarter · Q2
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Monitored issues related to taxation of offshore entities and corporate tax reform.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2015 · first_quarter · Q1
Issues related to minority cardiovascular health.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2015 · first_quarter · Q1
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Dormant Therapies Act in 21st Century Cures discussion draft.
Monitored issues related to taxation of offshore entities and corporate tax reform.
THORN RUN PARTNERS ON BEHALF OF ARBOR PHARMACEUTICALS, LLC via FORGE FEDERAL AFFAIRS LLC
2015 · first_quarter · RR
Issues related to minority cardiovascular health.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2014 · fourth_quarter · Q4
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2014 · third_quarter · Q3
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Monitored issues related to taxation of offshore entities and corporate tax reform.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2014 · second_quarter · Q2
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2014 · first_quarter · Q1
Monitored issues related to taxation of offshore entities and corporate tax reform.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2013 · fourth_quarter · Q4
Monitored issues related to taxation of offshore entities and corporate tax reform.
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2013 · third_quarter · Q3
Issues related to Medicare Part D Drug Rebate proposal in budget proposals. Encourage congressional support for Medicare coverage of amyloid imaging brain scans for diagnosis of early Alzheimer's.
Monitored issues related to taxation of offshore entities and corporate tax reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2013 · second_quarter · Q2
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Monitored issues related to taxation of offshore entities and corporate tax reform.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2013 · first_quarter · Q1
Monitored issues related to taxation of offshore entities and corporate tax reform.
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · fourth_quarter · 4A
Issues related to Medicare Part D in the Fiscal Cliff legislation, American Taxpayers Relief Act (H.R.8).
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Issues related to S.2105, Cybersecurity Act of 2012.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · fourth_quarter · Q4
Issues related to the taxation of offshore entities. Issues related to H.R.8, American Taxpayer Relief Act of 2012 (Fiscal Cliff legislation).
Issues related to Medicare Part D in the Fiscal Cliff legislation, American Taxpayers Relief Act (H.R.8).
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
ESCAPE MEDIA GROUP, INC. via FORGE FEDERAL AFFAIRS LLC
2012 · fourth_quarter · Q4
Issues related to immigration requirements for technology workers.
Issues related to online intellectual property rights enforcement and online privacy.
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · third_quarter · Q3
Issues related to Medicare Part D.
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Issues related to the taxation of offshore entities.
ESCAPE MEDIA GROUP, INC. via FORGE FEDERAL AFFAIRS LLC
2012 · third_quarter · Q3
Issues related to online intellectual property rights enforcement and online privacy.
Issues related to immigration requirements for technology workers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · second_quarter · Q2
Issues related to Medicare Part D.
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Issues related to the taxation of offshore entities.
ESCAPE MEDIA GROUP, INC. via FORGE FEDERAL AFFAIRS LLC
2012 · second_quarter · Q2
Issues related to online intellectual property rights enforcement and online privacy.
Issues related to immigration requirements for technology workers.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · first_quarter · Q1
Issues related to Prescription Drug User Fee Act (PDUFA).
Issues related to the taxation of offshore entities.
Issues related to Medicare Part D.
ESCAPE MEDIA GROUP, INC. via FORGE FEDERAL AFFAIRS LLC
2012 · first_quarter · Q1
Issues related to immigration requirements for technology workers.
Issues related to online intellectual property rights enforcement and online privacy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LILLY USA LLC via FORGE FEDERAL AFFAIRS LLC
2012 · first_quarter · RR
Issues related to prescription drug user fee act (PDUFA), taxation of offshore entities, patent/IP protections for biotech and pharmaceutical drugs, Medicare Part D.
Issues related to prescription drug user fee act (PDUFA), taxation of offshore entities, patent/IP protections for biotech and pharmaceutical drugs, Medicare Part D.
Issues related to prescription drug user fee act (PDUFA), taxation of offshore entities, patent/IP protections for biotech and pharmaceutical drugs, Medicare Part D.
ESCAPE MEDIA GROUP, INC. via FORGE FEDERAL AFFAIRS LLC
2012 · first_quarter · RR
Issues related to online intellectual property rights enforcement, online privacy, and immigration requirements for technology workers.
Issues related to online intellectual property rights enforcement, online privacy, and immigration requirements for technology workers.
Filing targets: HOUSE OF REPRESENTATIVES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary. Issues related to IP protections for pharmaceuticals and biologics in Trans Pacific Partnership trade agreement.
Filing targets: HOUSE OF REPRESENTATIVES
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary. Issues related to IP protections for pharmaceuticals and biologics in Trans Pacific Partnership trade agreement.
Issues related to Medicare Part D reform proposals in budget and funding measures. Issues related to CMS initiative on Medicare Part B Drug Payment Model.
Filing targets: HOUSE OF REPRESENTATIVES
Issues related to pricing of prescription drugs. Opposition to prescription drug importation. Support for funding of Department of Homeland Security drug interdiction efforts.
Monitored issues related to taxation of offshore revenue and corporate tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D reform proposals in budget and funding measures. Issues related to CMS initiative on Medicare Part B Drug Payment Model.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform. Supporting The Defend Trade Secrets Act of 2015 (S.1890, H.R.3326).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for inclusion of Dormant Therapies Act in H.R.6, 21st Century Cures Act. Issues related to patent reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issue involving invalidation of U.S. pharmaceutical company patents by Canadian judiciary.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitored issues related to taxation of offshore entities and corporate tax reform.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Filing targets: HOUSE OF REPRESENTATIVES
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitored issues related to taxation of offshore entities and corporate tax reform.
Issues related to Medicare Part D Drug Rebate proposal in budget proposals.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to patent/IP protections for biotech and pharmaceutical drugs. Support for Modern Cures Act (H.R. 3116).
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Monitored issues related to S. 21 Cybersecurity Act of 2013 and Executive Order on cybersecurity.
Filing targets: HOUSE OF REPRESENTATIVES
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Filing targets: HOUSE OF REPRESENTATIVES
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the taxation of offshore entities. Issues related to H.R.8, American Taxpayer Relief Act of 2012 (Fiscal Cliff legislation).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
Issues related to Prescription Drug User Fee Act (PDUFA).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Prescription Drug User Fee Act (PDUFA).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to patent/IP protections for biotech and pharmaceutical drugs.
Issues related to prescription drug user fee act (PDUFA), taxation of offshore entities, patent/IP protections for biotech and pharmaceutical drugs, Medicare Part D.